This effect may be particularly relevant in Africa, where endemic coinfections may contribute to disease progression, perhaps as a consequence of enhanced immune activation. We investigated the expression of CD38 and human leukocyte antigen (HLA)-DR on T cells in 168 HIV-seropositive volunteers in Uganda. We observed higher levels of CD4 + and CD8 + T cell activation in Uganda, compared with those reported in previous studies from Western countries. Coexpression of CD38 and HLA-DR on both CD4 + and CD8 + T cell subsets was directly correlated with viral load and inversely correlated with CD4 + T cell counts. In antiretroviral therapy (ART)-naive volunteers, viral load and CD4 + T cell count had stronger associations with CD8 + and CD4 + T cell activation, respectively. Virus suppression by ART was associated with a reduction in T cell activation, with a stronger observed effect on reducing CD8 + compared with CD4 + T cell activation. The presence of coinfection was associated with increased CD4 + T cell activation but, interestingly, not with increased CD8 + T cell activation. Our results suggest that distinct mechanisms differentially drive activation in CD4 + and CD8 + T cell subsets, which may impact the clinical prognostic values of T cell activation in HIV infection.
Immune activation has been suggested to be a stronger predictor of HIV disease progression than CD4 + T cell count or viral load alone [1] [2] [3] [4] and may even predict antiretroviral therapy (ART) treatment failure [5, 6] . Despite the strong correlation between T cell activation and clinical outcome, the exact mechanism by which HIV activates the immune system remains unresolved. Direct antigen-driven T cell activation by HIV and coinfections, nonspecifi bystander activation, and homeostatic proliferation have all been proposed as potential factors that drive immune activation [7] [8] [9] [10] . Regardless of the mechanisms involved, T cell activation, and not direct viral infection of T cells, is believed to be the major cause of CD4 + T cell depletion in HIV infection, through a process of activation-induced cell death (AICD) [2, 7, [11] [12] [13] . Correlation of disease progression with immune activation previously has been established mainly in individuals infected with clade B viruses and primarily in developed countries. In sub-Saharan Africa, where nonclade B viruses predominate and where coinfection is frequent, relatively few studies have addressed the relevance of immune activation to HIV disease prognosis. Higher levels of T cell activation have been reported in HIV-seronegative Africans [14] and have been attributed to frequent infections by various pathogens endemic in this region. Indeed, several studies from Ethiopia have suggested that chronic immune activation associated with parasitic infections can drive CD4 + T cell depletion in HIV-seronegative individuals [3, 15, 16] . Given these observations, plus theoretical arguments that immune activation associated with endemic coinfections may promote more-rapid HIV disease progression in Africa [17, 18] , we investigated the effect of HIV infection on immune activation in a cohort of HIVseropositive Ugandans. The association between viral load, CD4 + T cell counts, and T cell activation was examined in the context of ART and HIV coinfection. We analyzed CD4 + and CD8 + T cell populations independently, to evaluate the hypothesis that factors mediating immune activation may differentially affect the activation state of these T cell subsets.
SUBJECTS, MATERIALS, AND METHODS

Study population and design.
A total of 168 HIV-1-seropositive and 25 HIV-1-seronegative Ugandan adults visiting the HIV clinic at the Joint Clinical Research Centre in Kampala were enrolled in our cross-sectional study. Demographic information was compiled at the time of enrollment and blood draw. Volunteers were either ART naive or receiving treatment and were at all stages of disease. Diseases that are of high prevalence and endemic in Uganda were chosen as HIV-associated coinfections and were define as clinically reported presence of Mycobacterium tuberculosis, cytomegalovirus (CMV), Cryptococcus neoformans, Candida albicans, Pneumocystis carinii, Toxoplasma gondii, herpes simplex virus, herpes zoster, malaria, or helminth infection (as reported by physicians at the time blood was drawn). All individuals with tuberculosis (TB) were in their second to ninth month of anti-TB therapy. Exclusion criteria included an age of !18 years, pregnancy, active TB (define as suspected untreated TB or as TB during the firs 2 months of anti-TB therapy), or moribund status. Institutional review board approval was obtained from the California Department of Health Services; the University of California, San Francisco; and the Joint Clinical Research Center, Kampala. All study participants gave written, informed consent.
T cell immunophenotyping. ). Seventyfiv percent of volunteers were ART naive. Of the participants receiving ART, 42% had undetectable viral loads. On the basis of World Health Organization clinical classification the participants' HIV disease stages were as follows: 8% had stage 1 disease, 32% stage 2, 40% stage 3, 10% stage 4, and 10% stage "unknown." Twenty-eight percent of the cohort had physicianreported presence of at least 1 coinfection at the time that blood was drawn. TB was the most common coinfection (40%), followed by candida (30%), malaria (13%), and herpes zoster (13%). All treated individuals were receiving a regimen containing nucleoside analogues; 82% were also receiving a nonnucleoside reverse-transcriptase inhibitor, and 16% were receiving a protease inhibitor.
Twenty-fiv healthy HIV-seronegative adult Ugandans were ). This range of CD4 + T cell counts is similar to that reported in previous studies from Uganda [19] .
Immune activation in HIV-seropositive and -seronegative Ugandans. Activated T cells were define by coexpression of CD38 and HLA-DR (see figu e A1 in the Appendix, which appears only in the electronic edition of the Journal). To avoid intersample variability, all gates were preset and define using HIV-seronegative samples. HIV-seronegative Ugandans (n p ) had median levels of CD4 + and CD8 + T cell activation (5% 25 and 13%, respectively) similar to those reported in previous studies of HIV-seronegative Ethiopians (7%-8% and 12%-15%, respectively) [14] or multivariate analyses. Interestingly, in both univariate and multivariate models, coinfection was associated with increased HLA-DR expression only on CD4 + , but not CD8 + , T cells.
Relative effect of CD4
+ T cell count and viral load on T cell activation. The relative strengths of the associations of viral load and CD4 + T cell count with T cell activation was examined by measuring the contribution of these factors to the increment increase in the R 2 value, by use of the regression analysis model. We firs focused on the ART-naive cohort and calculated incremental changes in R 2 values for CD4 + T cell count and viral load when subsequent variables were added to the model. As shown in table 3, CD4 + T cell count was more strongly associated with CD4 + T cell activation than with CD8 + T cell activation when viral load was controlled for (R 2 increment of .19 vs. .02, respectively). In contrast, viral load had a stronger association with CD8 + T cell activation when CD4 + T cell count was controlled for (R 2 increment of .12 vs. .03). We next measured the association of ART with T cell activation.
Controlling for CD4
+ T cell count, we found that, when viral load was fully suppressed, the incremental increases in R 2 values were .12 and .30 for CD4 + and CD8 + T cell activation, respectively, suggesting that ART has a stronger effect on CD8 + T cell activation (table 3) .
DISCUSSION
Immune activation is predictive of HIV disease progression in ART-naive populations and has been associated with lower gains in CD4 + T cell counts after initiation of ART [4, 6, [20] [21] [22] . However, these significan associations mostly have been studied in North America and Europe, where HIV-1 clade B viruses predominate [1, 4-6, 20, 23-26] . The factors that influenc immune activation and its role as a clinical predictor in sub-Saharan Africa, where non-clade B viruses predominate and coinfection is prevalent, has yet to be established. In a cross-sectional study of HIV-seropositive Ugandan adults, we found dramatically elevated levels of T cell activation and investigated factors that may be responsible. We demonstrated that viral load, CD4 + T cell count, and coinfection are all strongly associated with T cell activation in this population. Interestingly, each factor was differentially associated with individual activation markers and also had distinct associations with CD4 + and CD8 + T cell lineages. The level of immune activation in HIV-seronegative volunteers in our Ugandan study population is up to 3-fold higher than those previously observed in HIV-seronegative cohorts from the United States or Europe [27, 28] . In this regard, our finding are in agreement with those of previous studies demonstrating higher levels of T cell activation in HIV-seronegative Africans [17, [29] [30] [31] . On the basis of our analysis, we cannot conclude whether this observed phenomenon is a consequence of environmental factors, including endemic infection, or whether genetic influence are partly responsible.
The immune activation profil in our cohort of HIV-seropositive Ugandans shows a striking increase in CD4 + and CD8 + T cell activation, much higher than that previously reported in the United States or Europe [2, 20, 28, 32, 33] , although direct comparisons between studies are complicated by differences in analyses. HIV-seropositive Ugandan volunteers have nearly 2-fold higher levels of T cell activation than do HIV-seropositive volunteers in more-developed regions. Lower CD4 + T cell counts, higher viral loads, and the presence of frequent endemic coinfection likely contribute to the observed high levels of activation.
Our study demonstrated that both CD4 + T cell count and viral load had significan associations with both CD4 + and CD8 + T cell activation, similar to what was found in previous studies [7, 20] . However, our data revealed that viral load and CD4 and CD4 + T cell count was no longer significan in our cohort in multivariate analyses after viral load was controlled for. This suggests that previously reported associations between CD4 + T cell depletion and CD8 + T cell activation, which were based on coexpression of HLA-DR and CD38, may be indirect and attributable to the relationship between increasing viral loads and decreasing CD4 + T cell counts. Consistent with the findin that viral load preferentially modulates CD8 + T cell activation, viral suppression by ART was found to have a stronger association with reduced CD8 + T cell activation in our study. These observed differences are potentially attributable to the distinct proliferative capacity and homeostatic proliferation pathways for CD4 + and CD8 + T cells [34, 35] . However, it is likely that complex factors mediate these differential effects on T cell subset activation.
In addition to viral load and CD4 + T cell count, coinfection is associated with changes in CD4 + T cell activation profiles and this effect appears to be independent of these other factors. In contrast, coinfection had no statistically significan association with CD8 + T cell activation in multivariate analysis, although there was a trend in the same direction. Activation of the immune system by exogenous stimuli, such as immunizations and copathogens, may enhance HIV replication, increase plasma viral load [36] [37] [38] , and worsen prognosis [39] . Since we observed an association between coinfection and CD4 + T cell activation that was independent of viral load and CD4 + T cell count, our data suggest that the presence of coinfection enhances immune activation directly, and not indirectly through increased levels of HIV replication or stages of immunodeficienc .
Numerous studies have confi med that TB and sexually transmitted diseases (STDs) are associated with increased viral load; however, data concerning the effect of coinfection on immune activation have been conflictin [18, [40] [41] [42] . For example, whereas coinfection with STDs [43] and TB [41, 44] have not been associated with increased immune activation in several recent studies in Africa, hepatitis C has been linked to increased CD4 + and CD8 + T cell activation in the United States [6] . Our data suggest that the association between CD4 + T cell activation and coinfection is primarily driven by HLA-DR expression. These finding are consistent with the observation by Orendi et al. that patients receiving highly active ART who have an opportunistic infection have increased HLA-DR expression on CD4 + T cells but no change in HLA-DR or CD38 expression on CD8 + T cells [20] . In our study, the association between HIV coinfection and CD4 + T cell activation alone suggests that infections endemic in Uganda might play a role in AICD-mediated CD4 + T cell depletion. In addition, it raises the concern that coinfection could represent a major confounding variable in CD4 + -specifi activation analysis. Whether coinfections are acting additively or synergistically with HIV to increase immune activation remains unresolved. Interestingly, we did not observe an association between immune activation and CD4 + T cell count in healthy HIV-seronegative Ugandans. It is possible that the effect on activation requires preexisting HIV infection. Alternatively, the lower CD4 + T cell counts in Ugandans might be due to a cumulative history of numerous infections that would not necessarily be reflecte in the activation state at the time that blood was drawn. The mechanism surrounding preferential activation of CD4 + , but not CD8 + , T cells by coinfections is also unclear and may depend on the type of pathogen present. Perhaps viral coinfections, such as with hepatitis C virus, have stronger effects on CD8 + T cells, whereas other pathogens have more of an effect on CD4 + T cells. In the Ugandan population in our study, the predominant HIV coinfections were parasitic, fungal, and mycobacterial, which may explain the stronger associations with CD4 + T cell activation. The sample size and the physician-based reporting of coinfection in our study did not allow further examination of whether specifi endemic diseases or repeated coinfections contributed to the observed elevated immune activation. Several immunophenotypic markers have been used to evaluate T cell activation ex vivo, although HLA-DR and CD38 are probably the most well-characterized markers of immune activation in HIV infection. Interestingly, individual analysis of CD38 and HLA-DR in the population in our study suggests that not only do these 2 activation markers have distinct associations with viral load, CD4 + T cell count, and coinfection, but they also behave differently on CD4 + and CD8 + T cells.
CD38 appears to be up-regulated on both CD4 + and CD8 + T cells in response to viral load, but its expression is not associated with CD4 + T cell count in either subset in multivariate analysis.
In contrast, HLA-DR up-regulation on CD4 + T cells is associated with viral load, CD4 + T cell count, and presence of coinfection, with no correlations in the CD8 + T cell population. Thus, the use of HLA-DR up-regulation as a single activation immunophenotype for CD8 + T cells may be less valid as a prognostic marker in HIV infection. Reliance on immune activation profile to provide cost-effective information on clinical prognosis for HIV infection in Africa clearly will require further examination of the multiple factors influencin the differential expression of these markers on T cell subsets. Our study reports some of the highest levels of immune activation in HIV infection and addresses the relatively understudied area of immune activation in sub-Saharan Africa [29, 45] . HIV infection in Uganda is caused by multiple endemic viral strains (subtypes A, C, and D [46, 47] ), and it is unclear whether this contributes to the high level of activation observed in our study. Certainly, the increased prevalence of coinfection and higher baseline activation levels also play a role. In addition, it is unclear whether the increased activation we observe will influenc HIV disease outcome and, perhaps, response to treatment in Africa. A longitudinal study in these regions of sub-Saharan Africa that addresses these factors will be necessary before the true impact of immune activation and its contribution to disease progression can be assessed.
